+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myeloma"

Hematological Malignancies: Global Strategic Business Report - Product Thumbnail Image

Hematological Malignancies: Global Strategic Business Report

  • Report
  • February 2024
  • 193 Pages
  • Global
From
Multiple Myeloma Global Market Report 2023 - Product Thumbnail Image

Multiple Myeloma Global Market Report 2023

  • Report
  • September 2023
  • 175 Pages
  • Global
From
From
From
Multiple Myeloma Epidemiology Analysis and Forecast to 2032 - Product Thumbnail Image

Multiple Myeloma Epidemiology Analysis and Forecast to 2032

  • Report
  • November 2023
  • 47 Pages
  • Global
From
From
Multiple Myeloma: Update Bulletin #2 - Product Thumbnail Image

Multiple Myeloma: Update Bulletin #2

  • Newsletter
  • February 2024
  • Global
From
From
Car T-Cell Therapy for Multiple Myeloma - Pipleine Insight, 2021 - Product Thumbnail Image

Car T-Cell Therapy for Multiple Myeloma - Pipleine Insight, 2021

  • Clinical Trials
  • September 2021
  • 60 Pages
  • Global
From
From
From
From
Disease Analysis: Multiple Myeloma - Product Thumbnail Image

Disease Analysis: Multiple Myeloma

  • Report
  • May 2021
  • 134 Pages
  • Global
Multiple Myeloma Pricing, Reimbursement, and Access - Product Thumbnail Image

Multiple Myeloma Pricing, Reimbursement, and Access

  • Report
  • March 2019
  • 85 Pages
  • Global
Loading Indicator

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of hematological malignancy, which is a cancer of the blood or bone marrow. Myeloma is the second most common type of hematological malignancy, after lymphoma. Symptoms of myeloma include bone pain, anemia, frequent infections, and kidney problems. Treatment options include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. The myeloma market is a subset of the hematology market, which is a large and growing market. The market is driven by the increasing prevalence of hematological malignancies, as well as advances in treatment options. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed. Some companies in the myeloma market include Bristol-Myers Squibb, Celgene, Novartis, and Takeda. Show Less Read more